Physician profile
Joseph Jeu
NPI 1508849647
$2,463.45
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.10 · 2020: $29.57 · 2021: $65.15 · 2022: $260 · 2023: $639 · 2024: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.42 | 2021-2024 | |
| Novo Nordisk INC | $318.59 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $241.88 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $230.15 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $220.50 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $134.27 | 2022-2024 | |
| Glaxosmithkline, LLC. | $85.21 | 2019-2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.77 | 2023-2024 | Jardiance, Ofev |
| Abbott Laboratories | $75.46 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $69.54 | 2019-2024 | Repatha, Otezla, Evenity |
| E.R. Squibb & Sons, L.L.C. | $66.75 | 2023-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $61.09 | 2024 | Spravato |
| Astellas Pharma US INC | $55.01 | 2023-2024 | Veozah |
| Dexcom, INC. | $54.81 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $49.54 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $37.13 | 2023-2024 | Unithroid |
| Xeris Pharmaceuticals, INC. | $36.42 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $34.55 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $29.15 | 2024 | |
| Axsome Therapeutics, INC. | $23.18 | 2024 | Auvelity |
| Neos Therapeutics, LP | $21.41 | 2024 | Adzenys Xr-Odt |
| Sanofi-Aventis U.S. LLC | $21.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.44 | 2023 | Cycloset |
| Novartis Pharmaceuticals Corporation | $17.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jeu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.